A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
- DOI
- 10.1038/s41416-025-03090-6
- Published
- 2025 Oct
- Container
- British journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41416-025-03090-6,
title = {A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.},
author = {Sooi K and Tan TZ and Kim JW and Lee JY and Kim BG and Micklem D and Jackson A and Pinato DJ and Gourley C and Kristeleit R and Blagden SP and Bjorge L and Tan DSP},
year = {2025},
journal = {British journal of cancer},
doi = {10.1038/s41416-025-03090-6},
url = {https://doi.org/10.1038/s41416-025-03090-6}
}RIS
TY - JOUR TI - A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients. AU - Sooi K AU - Tan TZ AU - Kim JW AU - Lee JY AU - Kim BG AU - Micklem D AU - Jackson A AU - Pinato DJ AU - Gourley C AU - Kristeleit R AU - Blagden SP AU - Bjorge L AU - Tan DSP PY - 2025 JO - British journal of cancer DO - 10.1038/s41416-025-03090-6 UR - https://doi.org/10.1038/s41416-025-03090-6 ER -
APA
K, S., TZ, T., JW, K., JY, L., BG, K., D, M., A, J., DJ, P., C, G., R, K., SP, B., L, B., & DSP, T. (2025). A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.. British journal of cancer. https://doi.org/10.1038/s41416-025-03090-6
Source records
- pubmed · retrieved 2026-09-25T20:49:29.975Z